Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Wall Brett A.	2. Date of Event Requiring Statement (MM/DD/YYYY) 11/1/2019	3. Issuer Name and Ticker or Trading Symbol Medtronic plc [MDT]
(Last)        (First)        (Middle) 710 MEDTRONIC PARKWAY, LC300	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) EVP & Group Pres Restora Thera /
(Street) MINNEAPOLIS, MN 55432       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	13075 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	10/28/2020 (2)	10/28/2029	Ordinary Shares	22579	$106.22	D
Stock Option (Right to Buy)	8/3/2016 (2)	8/3/2025	Ordinary Shares	11154	$78.00	D
Stock Option (Right to Buy)	8/3/2016 (2)	8/3/2025	Ordinary Shares	1283	$78.00	D
Stock Option (Right to Buy)	8/1/2017 (2)	8/1/2026	Ordinary Shares	11356	$88.06	D
Stock Option (Right to Buy)	8/1/2017 (2)	8/1/2026	Ordinary Shares	1136	$88.06	D
Stock Option (Right to Buy)	7/31/2018 (2)	7/31/2027	Ordinary Shares	11910	$83.97	D
Stock Option (Right to Buy)	7/31/2018 (2)	7/31/2027	Ordinary Shares	1191	$83.97	D
Stock Option (Right to Buy)	7/30/2019 (2)	7/30/2028	Ordinary Shares	16946	$89.08	D
Stock Option (Right to Buy)	7/30/2019 (2)	7/30/2028	Ordinary Shares	1695	$89.08	D
Stock Option (Right to Buy)	7/29/2020 (2)	7/29/2029	Ordinary Shares	24223	$103.26	D
Stock Option (Right to Buy)	7/29/2020 (2)	7/29/2029	Ordinary Shares	1615	$103.26	D
Stock Option (Right to Buy)	12/2/2014 (2)	12/1/2023	Ordinary Shares	12300	$47.00	D
Stock Option (Right to Buy)	6/29/2018 (3)	1/27/2025	Ordinary Shares	8018	$74.84	D

Explanation of Responses:
(1)	Includes grants of restricted stock units which vest on the listed date and for the listed number of shares if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth measured over the three most recently completed fiscal years exceeds a 3% cumulative compound annual growth rate (as determined by the Compensation Committee): (i) 3,129 restricted stock units that vest on 7/31/2020; (ii) 2,884 restricted stock units that vest on 7/30/2021; and (iii) 7,062 restricted stock units that vest on 7/29/2022.
(2)	These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.
(3)	This option became exercisable on June 29, 2018, subject to Medtronic plc's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Wall Brett A. 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS, MN 55432			EVP & Group Pres Restora Thera

Signatures
/s/ Perry F. Sekus, attorney-in-fact		11/7/2019
**Signature of Reporting Person		Date